CMS is considering reforms to reduce insurer use of prior authorizations, which increasingly delay or deny access to essential care.

Former President Trump’s “Most Favored Nation” drug pricing proposal is back, raising questions about price setting and pharma incentives.

Senator Cassidy spotlighted how pharmacy chains like CVS and Walgreens profit from the 340B program, intensifying calls for reform.

PBM practices are drawing bipartisan criticism, with advocates claiming these middlemen inflate drug costs while burdening small businesses.

Biopharma leaders are warning that without predictable regulatory policy, innovation may stall—while others argue innovation without access is meaningless.

Employers are scaling patient advocacy programs to improve benefit navigation and cut unnecessary spend—now serving 6 million lives through Elevance alone.

Despite patient affordability crises, health system CEOs collectively earned over $100 million last year—with minimal emphasis on patient experience metrics.

A new lawsuit from Tenet hospitals challenges Leapfrog’s hospital grading system, alleging unfair pay-to-play schemes that obscure transparency goals.

Charities are stepping in where traditional pharma fails—launching and financing gene therapy programs for ultra-rare conditions.

AI is already proving valuable in pharma—not just in R&D, but in streamlining operations and reducing development waste.

The FDA approved the first blood test to diagnose Alzheimer’s—an innovation that promises earlier detection but raises affordability and access questions.

Another must view from the folks at ADAP Advocacy on 340B and it being the next “too big to fail” in our economy. We need more transparency! Watch here

At the Asembia AXS25 Summit, leaders called out the need to balance equity investments with human-centered practices that drive trust.

Blue Shield of California exposed data from over 4 million patients to Google—raising urgent concerns about consent, privacy, and patient autonomy.

DEI is under fire nationally, but advocates argue the problem isn’t the mission—it’s the message. Clearer communication may be the key to progress.

Advocacy is evolving: industry insiders warn that without standards and measurement, it risks becoming symbolic rather than strategic.

Social determinants of health (SDOH) are driving more conversations about risk, follow-up, and the gaps created when systems assume access equals engagement.

We’re proud to sponsor the Walk It Off series by Matthew Zachary and the Out of Patients podcast—a thought-provoking exploration of what it means to face cancer as a man in a culture that too often says, “walk it off.” I know that phrase all too well—especially after breaking my neck.

Leapfrog’s latest hospital safety ratings show improvement—thanks in part to AI-powered predictive analytics and tech-driven workflows.

Pfizer is modeling a new path for drug development by embedding patient voice directly into research and clinical design processes. It’s not just PR—it’s operational strategy.

Speaking of transformative tech, we are proud to be on the Out of Patients podcast with Matthew Zachary, partnering with Invivyd, to bring forth a message of knowledge and empowerment to the cancer patient community. Take a listen to this episode here.